Therapeutic considerations for Mdm2: not just a one trick pony

Bibliography

• Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 1991;10(6):1565-9
   PubMed Web of Science ®Google Scholar
• Linke K, Mace PD, Smith CA, et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008;15(5):841-8
   PubMed Web of Science ®Google Scholar
• Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274(5289):948-53
   PubMed Web of Science ®Google Scholar
• Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5(1):27-41
   PubMed Web of Science ®Google Scholar
• Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358(6381):80-3
   PubMed Web of Science ®Google Scholar
• Sigalas I, Calvert AH, Anderson JJ, et al. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2(8):912-7
   PubMed Web of Science ®Google Scholar
• Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005;102(3):731-6
   PubMed Web of Science ®Google Scholar
• Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103(2):321-30
   PubMed Web of Science ®Google Scholar
• Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 2003;63(10):2616-23
   PubMed Web of Science ®Google Scholar
• Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119(5):591-602
   PubMed Web of Science ®Google Scholar
• Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66(10):5104-10
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69(7):1237-45
   PubMed Web of Science ®Google Scholar
• Zauberman A, Barak Y, Ragimov N, et al. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. Embo J 1993;12(7):2799-808
   PubMed Web of Science ®Google Scholar
• Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994;8(15):1739-49
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387(6630):296-9
   PubMed Web of Science ®Google Scholar
• Bottger A, Bottger V, Garcia-Echeverria C, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997;269(5):744-56
   PubMed Web of Science ®Google Scholar
• Kulikov R, Winter M, Blattner C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 2006;281(39):28575-83
   PubMed Web of Science ®Google Scholar
• Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378(6553):206-8
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378(6553):203-6
   PubMed Web of Science ®Google Scholar
• Mendrysa SM, McElwee MK, Michalowski J, et al. mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation. Mol Cell Biol 2003;23(2):462-72
   PubMed Web of Science ®Google Scholar
• Jones SN, Sands AT, Hancock AR, et al. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci USA 1996;93(24):14106-11
   PubMed Web of Science ®Google Scholar
• Lundgren K, Montes de Oca Luna R, McNeill YB, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11(6):714-25
   PubMed Web of Science ®Google Scholar
• Schuster K, Harris LC. Selection for mutations in the cDNAs of transgenic mice upon expression of an embryonic lethal protein. Transgenic Res 2007;16(4):527-30
   PubMed Web of Science ®Google Scholar
• Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002;2(5):401-13
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 1996;12(11):2279-89
   PubMed Web of Science ®Google Scholar
• Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999;18(27):3923-9
   PubMed Web of Science ®Google Scholar
• Dobbelstein M, Wienzek S, Konig C, Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999;18(12):2101-6
   PubMed Web of Science ®Google Scholar
• Zeng X, Chen L, Jost CA, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999;19(5)3257-66
   PubMed Web of Science ®Google Scholar
• Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92(6)713-23
   PubMed Web of Science ®Google Scholar
• Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95(14)8292-7
   PubMed Web of Science ®Google Scholar
• Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998;17(17)5001-14
   PubMed Web of Science ®Google Scholar
• Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375(6533)694-8
   PubMed Web of Science ®Google Scholar
• Sdek P, Ying H, Zheng H, et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 2004;279(51)53317-22
   PubMed Web of Science ®Google Scholar
• Martin K, Trouche D, Hagemeier C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995;375(6533)691-4
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang H, Li M, et al. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005;24(48)7238-47
   PubMed Web of Science ®Google Scholar
• Uchida C, Miwa S, Kitagawa K, et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. Embo J 2005;24(1)160-9
   PubMed Web of Science ®Google Scholar
• Higashitsuji H, Higashitsuji H, Itoh K, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005;8(1):75-87
   PubMed Web of Science ®Google Scholar
• Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. Embo J 1996;15(19):5349-57
   PubMed Web of Science ®Google Scholar
• Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001;29(1):92-5
   PubMed Web of Science ®Google Scholar
• Meulmeester E, Frenk R, Stad R, et al. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 2003;23(14):4929-38
   PubMed Web of Science ®Google Scholar
• Stad R, Little NA, Xirodimas DP, et al. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2001;2(11):1029-34
   PubMed Web of Science ®Google Scholar
• Tanimura S, Ohtsuka S, Mitsui K, et al. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999;447(1):5-9
   PubMed Web of Science ®Google Scholar
• Kostic M, Matt T, Martinez-Yamout MA, et al. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 2006;363(2):433-50
   PubMedGoogle Scholar
• Migliorini D, Danovi D, Colombo E, et al. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 2002;277(9):7318-23
   PubMed Web of Science ®Google Scholar
• Kawai H, Wiederschain D, Kitao H, et al. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 2003;278(46):45946-53
   PubMed Web of Science ®Google Scholar
• Barboza JA, Iwakuma T, Terzian T, et al. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 2008;6(6):947-54
   PubMed Web of Science ®Google Scholar
• de Graaf P, Little NA, Ramos YF, et al. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 2003;278(40):38315-24
   PubMed Web of Science ®Google Scholar
• Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. Embo J 2004;23(7):1547-56
   PubMed Web of Science ®Google Scholar
• Nag A, Bagchi S, Raychaudhuri P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res 2004;64(22):8152-5
   PubMed Web of Science ®Google Scholar
• Itahana K, Mao H, Jin A, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007;12(4):355-66
   PubMed Web of Science ®Google Scholar
• Kobet E, Zeng X, Zhu Y, et al. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 2000;97(23):12547-52
   PubMed Web of Science ®Google Scholar
• Jin Y, Zeng SX, Dai MS, et al. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002;277(34):30838-43
   PubMed Web of Science ®Google Scholar
• Linares LK, Kiernan R, Triboulet R, et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 2007;9(3):331-8
   PubMed Web of Science ®Google Scholar
• Coutts AS, Boulahbel H, Graham A, La Thangue NB. Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep 2007;8(1):84-90
   PubMed Web of Science ®Google Scholar
• Minsky N, Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 2004;16(4):631-9
   PubMed Web of Science ®Google Scholar
• Minsky N, Shema E, Field Y, et al. Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol 2008;10(4):483-8
   PubMed Web of Science ®Google Scholar
• Marechal V, Elenbaas B, Piette J, et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 1994;14(11):7414-20
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999;19(3):1751-8
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000;20(9):3224-33
   PubMed Web of Science ®Google Scholar
• Lohrum MA, Ludwig RL, Kubbutat MH, et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003;3(6):577-87
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003;23(23):8902-12
   PubMed Web of Science ®Google Scholar
• Dai MS, Zeng SX, Jin Y, et al. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004;24(17):7654-68
   PubMed Web of Science ®Google Scholar
• Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004;279(43):44475-82
   PubMed Web of Science ®Google Scholar
• Elenbaas B, Dobbelstein M, Roth J, et al. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996;2(4):439-51
   PubMed Web of Science ®Google Scholar
• Lindstrom MS, Jin A, Deisenroth C, et al. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 2007;27(3):1056-68
   PubMed Web of Science ®Google Scholar
• Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004;5(5):465-75
   PubMed Web of Science ®Google Scholar
• Yu Y, Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 2006;26(10):3798-809
   PubMed Web of Science ®Google Scholar
• Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008;28(13):4365-76
   PubMed Web of Science ®Google Scholar
• Frum R, Busby SA, Ramamoorthy M, et al. HDM2-binding partners: interaction with translation elongation factor EF1alpha. J Proteome Res 2007;6(4):1410-7
   PubMed Web of Science ®Google Scholar
• Louria-Hayon I, Grossman T, Sionov RV, et al. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 2003;278(35):33134-41
   PubMed Web of Science ®Google Scholar
• Bernardi R, Scaglioni PP, Bergmann S, et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004;6(7):665-72
   PubMed Web of Science ®Google Scholar
• Wei X, Yu ZK, Ramalingam A, et al. Physical and functional interactions between PML and MDM2. J Biol Chem 2003;278(31):29288-97
   PubMed Web of Science ®Google Scholar
• Alt JR, Bouska A, Fernandez MR, et al. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 2005;280(19):18771-81
   PubMed Web of Science ®Google Scholar
• Bouska A, Lushnikova T, Plaza S, Eischen CM. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 2008;28(15):4862-74
   PubMed Web of Science ®Google Scholar
• Asahara H, Li Y, Fuss J, et al. Stimulation of human DNA polymerase epsilon by MDM2. Nucleic Acids Res 2003;31(9):2451-9
   PubMed Web of Science ®Google Scholar
• LaRusch GA, Jackson MW, Dunbar JD, et al. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 2007;67(2):450-4
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Ludwig RL, Woods DB, et al. Phosphorylation of HDM2 by Akt. Oncogene 2002;21(13):1955-62
   PubMed Web of Science ®Google Scholar
• Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003;278(16):13595-8
   PubMed Web of Science ®Google Scholar
• Roe JS, Kim H, Lee SM, et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006;22(3):395-405
   PubMed Web of Science ®Google Scholar
• Nieminen AL, Qanungo S, Schneider EA, et al. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 2005;204(2):364-9
   PubMed Web of Science ®Google Scholar
• Maya R, Balass M, Kim ST, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 2001;15(9):1067-77
   PubMed Web of Science ®Google Scholar
• Sionov RV, Moallem E, Berger M, et al. c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 1999;274(13):8371-4
   PubMed Web of Science ®Google Scholar
• Goldberg Z, Vogt Sionov R, Berger M, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. Embo J 2002;21(14):3715-27
   PubMed Web of Science ®Google Scholar
• Dias SS, Milne DM, Meek DW. c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF. Oncogene 2006;25(50):6666-71
   PubMed Web of Science ®Google Scholar
• Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 1997;57(22):5013-6
   PubMed Web of Science ®Google Scholar
• Fry DC, Emerson SD, Palme S, et al. NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR 2004;30(2):163-73
   PubMed Web of Science ®Google Scholar
• Gotz C, Kartarius S, Scholtes P, et al. Identification of a CK2 phosphorylation site in mdm2. Eur J Biochem 1999;266(2):493-501
   PubMedGoogle Scholar
• Weber HO, Ludwig RL, Morrison D, et al. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 2005;24(12):1965-72
   PubMed Web of Science ®Google Scholar
• Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001;98(20):11598-603
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3(11):973-82
   PubMed Web of Science ®Google Scholar
• Jackson MW, Patt LE, LaRusch GA, et al. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem 2006;281(24):16814-20
   PubMed Web of Science ®Google Scholar
• Lu X, Ma O, Nguyen TA, et al. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007;12(4):342-54
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273(22):13375-8
   PubMed Web of Science ®Google Scholar
• Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277(7):5484-9
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102(6):849-62
   PubMed Web of Science ®Google Scholar
• Mayo LD, Seo YR, Jackson MW, et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005;280(28):25953-9
   PubMed Web of Science ®Google Scholar
• Li AG, Piluso LG, Cai X, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 2006;23(4):575-87
   PubMed Web of Science ®Google Scholar
• Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 1997;14(15):1859-68
   PubMed Web of Science ®Google Scholar
• Murray JK, Gellman SH. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers 2007;88(5):657-86
   PubMed Web of Science ®Google Scholar
• Duncan SJ, Gruschow S, Williams DH, et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 2001;123(4):554-60
   PubMed Web of Science ®Google Scholar
• Stoll R, Renner C, Hansen S, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001;40(2):336-44
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang M, Chen J, et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett 2002;183(1):69-77
   PubMed Web of Science ®Google Scholar
• Galatin PS, Abraham DJ. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J Med Chem 2004;47(17):4163-5
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• D'Silva L, Ozdowy P, Krajewski M, et al. Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc 2005;127(38):13220-6
   PubMed Web of Science ®Google Scholar
• Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008;27(7):997-1003
   PubMed Web of Science ®Google Scholar
• Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005;48(4):909-12
   PubMed Web of Science ®Google Scholar
• Koblish HK, Zhao S, Franks CF, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006;5(1):160-9
   PubMed Web of Science ®Google Scholar
• Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279(51):53015-22
   PubMed Web of Science ®Google Scholar
• Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008;105(10):3933-8
   PubMed Web of Science ®Google Scholar
• Hardcastle IR, Ahmed SU, Atkins H, et al. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett 2005;15(5):1515-20
   PubMed Web of Science ®Google Scholar
• Hardcastle IR, Ahmed SU, Atkins H, et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem 2006;49(21):6209-21
   PubMed Web of Science ®Google Scholar
• Rothweiler U, Czarna A, Krajewski M, et al. Isoquinolin-1-one Inhibitors of the MDM2-p53 Interaction. ChemMedChem 2008
   PubMedGoogle Scholar
• Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005;7(6):547-59
   PubMed Web of Science ®Google Scholar
• Candeias MM, Malbert-Colas L, Powell DJ, et al. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008
   PubMedGoogle Scholar
• Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10(12):1321-8
   PubMed Web of Science ®Google Scholar
• Krajewski M, Ozdowy P, D'Silva L, et al. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005;11(11):1135-6; author reply 6-7
   PubMed Web of Science ®Google Scholar
• Duncan SJ, Cooper MA, Williams DH. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem Commun Camb 2003;(3):316-7
   PubMedGoogle Scholar
• Tsukamoto S, Yoshida T, Hosono H, et al. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorg Med Chem Lett 2006;16(1):69-71
   PubMed Web of Science ®Google Scholar
• Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006;49(12):3432-5
   PubMed Web of Science ®Google Scholar
• Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008;7(6):1533-42
   PubMed Web of Science ®Google Scholar
• Rothweiler U, Czarna A, Krajewski M, et al. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem 2008;3(7):1118-28
   PubMed Web of Science ®Google Scholar